Yayın:
A phase III, partially double-blinded study evaluating the efficacy and safety of peginterferon alfa-2a (40KD) (PEGASYS (R)) alone or in combination with lamivudine vs lamivudine in 546 patients with HBeAg-negative/anti-HBe-positive chronic hepatitis B.

Basit Görünüm
dc.contributor.authorMarcellin, P.
dc.contributor.authorLau, G.
dc.contributor.authorBonino, F.
dc.contributor.authorFarci, P.
dc.contributor.authorHadziyannis, S.
dc.contributor.authorJin, R.
dc.contributor.authorLu, Z.
dc.contributor.authorPiratvisuth, T.
dc.contributor.authorGermanidis, G.
dc.contributor.authorYurdaydın, C.
dc.contributor.authorDiago, M.
dc.contributor.authorLai, M.
dc.contributor.authorButton, P.
dc.contributor.authorPluck, N.
dc.contributor.buuauthorGürel, S.
dc.contributor.departmentTıp Fakültesi
dc.contributor.researcheridAAH-5364-2019
dc.contributor.researcheridABI-3764-2020
dc.date.accessioned2022-08-24T13:14:56Z
dc.date.available2022-08-24T13:14:56Z
dc.date.issued2003-10
dc.descriptionBu çalışma, 24-28 Ekim 2003 tarihleri arasında Boston, Massachusetts[Amerika Birleşik Devletleri]’nde düzenlenen 5. Annual Meeting of the Federation’da bildiri olarak sunulmuştur.
dc.description.sponsorshipAmer Assoc Study Liver Diseases
dc.identifier.citationMarcellin, P. vd. (2003). “A phase III, partially double-blinded study evaluating the efficacy and safety of peginterferon alfa-2a (40KD) (PEGASYS (R)) alone or in combination with lamivudine vs lamivudine in 546 patients with HBeAg-negative/anti-HBe-positive chronic hepatitis B”. Hepatology, 38(4), Supplement 1, 724A-725A.
dc.identifier.endpage725A
dc.identifier.issn0270-9139
dc.identifier.issue4, Supplement 1
dc.identifier.startpage724A
dc.identifier.urihttp://hdl.handle.net/11452/28349
dc.identifier.volume38
dc.identifier.wos000185816701180
dc.indexed.wosSCIE
dc.indexed.wosCPCIS
dc.language.isoen
dc.publisherWiley
dc.relation.collaborationYurt içi
dc.relation.collaborationYurt dışı
dc.relation.journalHematology
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectGastroenterology & hepatology
dc.subject.wosGastroenterology and hepatology
dc.titleA phase III, partially double-blinded study evaluating the efficacy and safety of peginterferon alfa-2a (40KD) (PEGASYS (R)) alone or in combination with lamivudine vs lamivudine in 546 patients with HBeAg-negative/anti-HBe-positive chronic hepatitis B.
dc.typeOther
dc.type.subtypeMeeting Abstract
dc.wos.quartileQ1
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi
local.indexed.atWOS

Dosyalar

Lisanslı seri

Şimdi gösteriliyor 1 - 1 / 1
Placeholder
Ad:
license.txt
Boyut:
1.71 KB
Format:
Item-specific license agreed upon to submission
Açıklama
İndir

Koleksiyonlar

İndeksli Yayınlar / Indexed Publications